Johnson & Johnson Announced the Failure of HIV Vaccine Trials in Africa
OREANDA-NEWS. The Johnson & Johnson vaccine against the human immunodeficiency virus during clinical trials in African countries showed an effectiveness of only 25% and could not provide sufficient protection against the virus. This is reported by Bloomberg with reference to the company's statement.
The clinical trial, which began in 2017, involved 2,600 women from Zambia, Zimbabwe, Malawi, Mozambique and South Africa. The adenovirus vaccine of four doses showed an effectiveness of only 25.2% with the minimum required effectiveness of 50%. Thus, 51 women were infected out of those who received the vaccine, while 63 were infected in the placebo group.
Johnson & Johnson said that the reseach is over, while the parallel study on homosexuals and transgender people in Europe and America, which began in 2019, will continue. Despite the failure, the head of the company's scientific service, Paul Stoffels, said that the limited effectiveness of the vaccine can help scientists move to a more effective treatment. According to him, the immune responses of the study participants will be analyzed, which will help to understand the causes of insecurity.